Nothing Special   »   [go: up one dir, main page]

MX2019007144A - Nuevos agonistas de tnfr y sus usos. - Google Patents

Nuevos agonistas de tnfr y sus usos.

Info

Publication number
MX2019007144A
MX2019007144A MX2019007144A MX2019007144A MX2019007144A MX 2019007144 A MX2019007144 A MX 2019007144A MX 2019007144 A MX2019007144 A MX 2019007144A MX 2019007144 A MX2019007144 A MX 2019007144A MX 2019007144 A MX2019007144 A MX 2019007144A
Authority
MX
Mexico
Prior art keywords
present
tnfr
tnfr agonists
relates
novel tnfr
Prior art date
Application number
MX2019007144A
Other languages
English (en)
Inventor
Blein Stanislas
Back Jonathan
Lissilaa Rami
Rousseau François
MACOIN Julie
STUTZ Cian
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of MX2019007144A publication Critical patent/MX2019007144A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion se refiere a una nueva clase de agonista de TNFR que comprende multiples secciones de union con al menos dos diferentes partes del mismo TNFR. La presente invencion tambien se refiere a metodos de activacion de los componentes del sistema inmune en un paciente, a traves de la administracion de un agonista de TNFR de conformidad con la presente invencion, asi como el uso de tales materiales para fines terapeuticos y para otros fines.
MX2019007144A 2016-12-19 2017-12-19 Nuevos agonistas de tnfr y sus usos. MX2019007144A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16205108 2016-12-19
PCT/EP2017/083632 WO2018115003A2 (en) 2016-12-19 2017-12-19 Novel tnfr agonists and uses thereof

Publications (1)

Publication Number Publication Date
MX2019007144A true MX2019007144A (es) 2019-10-07

Family

ID=57708364

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007144A MX2019007144A (es) 2016-12-19 2017-12-19 Nuevos agonistas de tnfr y sus usos.

Country Status (12)

Country Link
US (1) US20200347143A1 (es)
EP (1) EP3555134A2 (es)
JP (1) JP2020504105A (es)
KR (1) KR20190095941A (es)
CN (1) CN110291108A (es)
AU (1) AU2017384528A1 (es)
CA (1) CA3047059A1 (es)
EA (1) EA201991207A1 (es)
IL (1) IL267436A (es)
MX (1) MX2019007144A (es)
WO (1) WO2018115003A2 (es)
ZA (1) ZA201903934B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2953634B1 (en) 2013-02-07 2021-05-26 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
SG10201909806SA (en) * 2013-11-04 2019-11-28 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
IL260530B2 (en) 2016-01-11 2024-01-01 Inhibrx Inc Multispecific and multivalent 41BB-binding fusion proteins, preparations containing them and their uses
CN108883153A (zh) 2016-01-11 2018-11-23 印希比股份有限公司 多价和多特异性ox40结合融合蛋白
AU2017263833B2 (en) 2016-05-13 2023-08-03 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
US11242385B2 (en) 2017-04-13 2022-02-08 Agenus Inc. Anti-CD137 antibodies and methods of use thereof
EP3837285A1 (en) * 2018-08-13 2021-06-23 Inhibrx, Inc. Ox40-binding polypeptides and uses thereof
CN112955179A (zh) * 2018-08-20 2021-06-11 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族多肽
JP2022523333A (ja) 2019-01-30 2022-04-22 トゥルーバインディング，インコーポレイテッド 抗ｇａｌ３抗体およびその使用
CN114761430A (zh) * 2019-09-26 2022-07-15 奥里尼斯生物科学股份有限公司 靶向pd-l1的嵌合蛋白及其用途
WO2023122643A1 (en) * 2021-12-22 2023-06-29 Regents Of The University Of Minnesota Cd83 and allo- and autoimmune conditions
WO2024037626A1 (zh) * 2022-08-19 2024-02-22 盛禾(中国)生物制药有限公司 一种结合tnfr2和4-1bb的双特异性抗体
WO2024062092A1 (en) * 2022-09-22 2024-03-28 Julius-Maximilians-Universität Würzburg Anti-cd40 antibody constructs with high intrinsic agonism
WO2024204896A1 (en) * 2023-03-31 2024-10-03 Affyxell Therapeutics Co., Ltd. Genetically modified cells into which a nucleic acid encoding a stefin a protein variants specifically binding to tnfr2 or a fusion protein comprising the same has been introduced, and uses thereof
WO2024201144A1 (en) * 2023-03-31 2024-10-03 Affyxell Therapeutics Co., Ltd. Genetically modified cells comprising a nucleic acid encoding a tnfr2 binding agent and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5924939A (en) 1996-09-10 1999-07-20 Cobra Golf Incorporated Golf club head with a strike face having a first insert within a second insert
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP3239178A1 (en) 2007-12-14 2017-11-01 Bristol-Myers Squibb Company Binding molecules to the human ox40 receptor
UA121453C2 (uk) * 2008-04-11 2020-06-10 Чугей Сейяку Кабусікі Кайся Спосіб одержання фармацевтичної композиції, яка містить антитіло
EP2573175B1 (en) * 2010-05-18 2020-07-08 Medical and Biological Laboratories Co., Ltd. ANTIBODY CAPABLE OF BINDING TO TRANSFORMING GROWTH FACTOR ALPHA AND HAVING ANTIPROLIFERATIVE ACTIVITY ON CANCER HAVING Ras GENE MUTATION
AU2011293558B2 (en) 2010-08-23 2014-07-31 Board Of Regents, The University Of Texas System Anti-OX40 antibodies and methods of using the same
CA2827033A1 (en) * 2011-02-09 2012-08-16 Glaxosmithkline Llc Lyophilized formulations
SI2699601T1 (en) 2011-04-21 2018-04-30 Bristol-Myers Squibb Company PROTITOLIC POLYPETIDES AS THE CD40 ANTAGONISTS
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
EP2976361B1 (en) * 2013-03-18 2018-07-18 BiocerOX Products B.V. Humanized anti-cd134 (ox40) antibodies and uses thereof
MA40682B1 (fr) 2014-03-31 2020-01-31 Hoffmann La Roche Anticorps anti-ox40 et procédés d'utilisation correspondants
MX360295B (es) * 2014-05-29 2018-10-29 Medimmune Llc Proteinas de fusion del ligando de ox40 (ox40l) y sus usos.
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
AU2015342882B2 (en) * 2014-11-07 2021-05-20 F. Hoffmann-La Roche Ltd Improved IL-6 antibodies
EP3268037B1 (en) * 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
MX2017012805A (es) * 2015-04-07 2018-04-11 Genentech Inc Complejo de unión a antígenos con actividad agonista y métodos de uso.
WO2016179517A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
CA2987410A1 (en) * 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
UY36757A (es) 2015-06-29 2016-12-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
CA3002789A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
CN108883153A (zh) 2016-01-11 2018-11-23 印希比股份有限公司 多价和多特异性ox40结合融合蛋白

Also Published As

Publication number Publication date
WO2018115003A2 (en) 2018-06-28
AU2017384528A1 (en) 2019-07-04
WO2018115003A3 (en) 2018-08-09
ZA201903934B (en) 2020-11-25
KR20190095941A (ko) 2019-08-16
EA201991207A1 (ru) 2019-12-30
CA3047059A1 (en) 2018-06-28
US20200347143A1 (en) 2020-11-05
EP3555134A2 (en) 2019-10-23
IL267436A (en) 2019-08-29
CN110291108A (zh) 2019-09-27
JP2020504105A (ja) 2020-02-06

Similar Documents

Publication Publication Date Title
MX2019007144A (es) Nuevos agonistas de tnfr y sus usos.
WO2018083087A3 (en) Binding proteins
MX2022004374A (es) Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cancer.
PH12018501882A1 (en) Binding proteins and methods of use thereof
EP4344706A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
MX2018015853A (es) Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137).
PH12017500803A1 (en) Anti-pd-1 antibodies
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
PH12016501644A1 (en) Binding proteins and methods of use thereof
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
BR112016023948A2 (pt) proteínas fc multiméricas
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
MX370792B (es) Composiciones para usarse en el tratamiento de cáncer.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2018005544A (es) Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer.
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
TN2018000188A1 (en) Isoindole compounds
CO2017001601A2 (es) Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
AU2015278731B2 (en) Fused triterpene compounds and uses thereof
MX2019006446A (es) Métodos para inducir tolerancia inmunológica a factores de coagulación.

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: HITACHI ENERGY SWITZERLAND AG